Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 513 in Participants With Obesity
NCT06585462Phase 1Completed
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 513 in obesity and Overweight (2 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent Adverse Events at 150 days. Started Sep 2024; status: completed.
02
Drugs
AMG 513
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06585462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585462.